Where Will Exxon Stock Be in 5 Years?
For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…
Sell
49
CRL Quote, Financials, Valuation and Earnings
Last price:
$147.44
Seasonality move
:
4.04%
Day range:
$143.12 - $145.65
52-week range:
$91.86 - $254.15
Dividend yield:
0%
P/E ratio:
913.13x
P/S ratio:
1.85x
P/B ratio:
2.22x
Volume:
938K
Avg. volume:
1.2M
1-year change:
-34.71%
Market cap:
$7.1B
Revenue:
$4B
EPS (TTM):
-$0.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$941.9M | $2.07 | -4.1% | 42.66% | $156.14 |
|
DVA
DaVita
|
$3.2B | $2.02 | 5.28% | 10.44% | $162.92 |
|
JNJ
Johnson & Johnson
|
$21.6B | $2.58 | 1.79% | 38.86% | $169.18 |
|
LLY
Eli Lilly and
|
$12.7B | $3.46 | 26.87% | 68.59% | $951.98 |
|
MRNA
Moderna
|
$115.3M | -$3.11 | -49.84% | -11.55% | $47.64 |
|
UNH
UnitedHealth Group
|
$111.6B | $7.29 | 13.15% | 11% | $388.34 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$144.70 | $156.14 | $7.1B | 913.13x | $0.00 | 0% | 1.85x |
|
DVA
DaVita
|
$137.90 | $162.92 | $10.4B | 13.67x | $0.00 | 0% | 0.90x |
|
JNJ
Johnson & Johnson
|
$155.03 | $169.18 | $373B | 17.24x | $1.30 | 3.24% | 4.21x |
|
LLY
Eli Lilly and
|
$769.88 | $951.98 | $691.1B | 62.64x | $1.50 | 0.73% | 14.19x |
|
MRNA
Moderna
|
$27.46 | $47.64 | $10.6B | -- | $0.00 | 0% | 3.40x |
|
UNH
UnitedHealth Group
|
$303.22 | $388.34 | $275.1B | 12.70x | $2.10 | 2.77% | 0.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
44.01% | 1.720 | 33.75% | 0.94x |
|
DVA
DaVita
|
102.82% | 1.528 | 70.83% | 1.12x |
|
JNJ
Johnson & Johnson
|
40.08% | 0.110 | 13.1% | 0.96x |
|
LLY
Eli Lilly and
|
70.96% | -0.127 | 5.19% | 0.57x |
|
MRNA
Moderna
|
-- | -0.658 | -- | 3.92x |
|
UNH
UnitedHealth Group
|
46.1% | -0.103 | 16.7% | 0.77x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$317.7M | $74.7M | -0.52% | -0.87% | 6.49% | $112.4M |
|
DVA
DaVita
|
$983.9M | $433.3M | 7.42% | 38.96% | 13.07% | $36.8M |
|
JNJ
Johnson & Johnson
|
$14.5B | $6.3B | 19.44% | 30.18% | 63.19% | $3.4B |
|
LLY
Eli Lilly and
|
$10.5B | $5.4B | 24.21% | 78.25% | 29.07% | -$1.6B |
|
MRNA
Moderna
|
$17M | -$1.1B | -29.23% | -29.23% | -900% | -$1.2B |
|
UNH
UnitedHealth Group
|
$23.8B | $9.1B | 12.37% | 21.74% | 8.31% | $4.6B |
Charles River Laboratories International vs. Competitors
-
Which has Higher Returns CRL or DVA?
DaVita has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 5.05%. Charles River Laboratories International's return on equity of -0.87% beat DaVita's return on equity of 38.96%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B DVADaVita30.52% $2.00 $11.4B -
What do Analysts Say About CRL or DVA?
Charles River Laboratories International has a consensus price target of $156.14, signalling upside risk potential of 7.91%. On the other hand DaVita has an analysts' consensus of $162.92 which suggests that it could grow by 18.15%. Given that DaVita has higher upside potential than Charles River Laboratories International, analysts believe DaVita is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 DVADaVita1 8 0 -
Is CRL or DVA More Risky?
Charles River Laboratories International has a beta of 1.476, which suggesting that the stock is 47.571% more volatile than S&P 500. In comparison DaVita has a beta of 1.107, suggesting its more volatile than the S&P 500 by 10.674%.
-
Which is a Better Dividend Stock CRL or DVA?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DaVita offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International pays -- of its earnings as a dividend. DaVita pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or DVA?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than DaVita quarterly revenues of $3.2B. Charles River Laboratories International's net income of $25.5M is lower than DaVita's net income of $162.9M. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while DaVita's PE ratio is 13.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.85x versus 0.90x for DaVita. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.85x 913.13x $984.2M $25.5M DVADaVita0.90x 13.67x $3.2B $162.9M
-
Which has Higher Returns CRL or JNJ?
Johnson & Johnson has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 50.24%. Charles River Laboratories International's return on equity of -0.87% beat Johnson & Johnson's return on equity of 30.18%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B JNJJohnson & Johnson66.4% $4.54 $130.4B -
What do Analysts Say About CRL or JNJ?
Charles River Laboratories International has a consensus price target of $156.14, signalling upside risk potential of 7.91%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 9.13%. Given that Johnson & Johnson has higher upside potential than Charles River Laboratories International, analysts believe Johnson & Johnson is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 JNJJohnson & Johnson7 13 0 -
Is CRL or JNJ More Risky?
Charles River Laboratories International has a beta of 1.476, which suggesting that the stock is 47.571% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.
-
Which is a Better Dividend Stock CRL or JNJ?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.24% to investors and pays a quarterly dividend of $1.30 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or JNJ?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Charles River Laboratories International's net income of $25.5M is lower than Johnson & Johnson's net income of $11B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Johnson & Johnson's PE ratio is 17.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.85x versus 4.21x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.85x 913.13x $984.2M $25.5M JNJJohnson & Johnson4.21x 17.24x $21.9B $11B
-
Which has Higher Returns CRL or LLY?
Eli Lilly and has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 21.68%. Charles River Laboratories International's return on equity of -0.87% beat Eli Lilly and's return on equity of 78.25%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B LLYEli Lilly and82.53% $3.06 $54.4B -
What do Analysts Say About CRL or LLY?
Charles River Laboratories International has a consensus price target of $156.14, signalling upside risk potential of 7.91%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 23.65%. Given that Eli Lilly and has higher upside potential than Charles River Laboratories International, analysts believe Eli Lilly and is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 LLYEli Lilly and16 4 1 -
Is CRL or LLY More Risky?
Charles River Laboratories International has a beta of 1.476, which suggesting that the stock is 47.571% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.
-
Which is a Better Dividend Stock CRL or LLY?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or LLY?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Charles River Laboratories International's net income of $25.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Eli Lilly and's PE ratio is 62.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.85x versus 14.19x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.85x 913.13x $984.2M $25.5M LLYEli Lilly and14.19x 62.64x $12.7B $2.8B
-
Which has Higher Returns CRL or MRNA?
Moderna has a net margin of 2.59% compared to Charles River Laboratories International's net margin of -907.48%. Charles River Laboratories International's return on equity of -0.87% beat Moderna's return on equity of -29.23%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B MRNAModerna15.89% -$2.52 $10.1B -
What do Analysts Say About CRL or MRNA?
Charles River Laboratories International has a consensus price target of $156.14, signalling upside risk potential of 7.91%. On the other hand Moderna has an analysts' consensus of $47.64 which suggests that it could grow by 73.69%. Given that Moderna has higher upside potential than Charles River Laboratories International, analysts believe Moderna is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 MRNAModerna4 17 1 -
Is CRL or MRNA More Risky?
Charles River Laboratories International has a beta of 1.476, which suggesting that the stock is 47.571% more volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.
-
Which is a Better Dividend Stock CRL or MRNA?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or MRNA?
Charles River Laboratories International quarterly revenues are $984.2M, which are larger than Moderna quarterly revenues of $107M. Charles River Laboratories International's net income of $25.5M is higher than Moderna's net income of -$971M. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.85x versus 3.40x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.85x 913.13x $984.2M $25.5M MRNAModerna3.40x -- $107M -$971M
-
Which has Higher Returns CRL or UNH?
UnitedHealth Group has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 5.74%. Charles River Laboratories International's return on equity of -0.87% beat UnitedHealth Group's return on equity of 21.74%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B UNHUnitedHealth Group21.7% $6.85 $186.4B -
What do Analysts Say About CRL or UNH?
Charles River Laboratories International has a consensus price target of $156.14, signalling upside risk potential of 7.91%. On the other hand UnitedHealth Group has an analysts' consensus of $388.34 which suggests that it could grow by 27.7%. Given that UnitedHealth Group has higher upside potential than Charles River Laboratories International, analysts believe UnitedHealth Group is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 UNHUnitedHealth Group14 5 1 -
Is CRL or UNH More Risky?
Charles River Laboratories International has a beta of 1.476, which suggesting that the stock is 47.571% more volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.442, suggesting its less volatile than the S&P 500 by 55.841%.
-
Which is a Better Dividend Stock CRL or UNH?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.77% to investors and pays a quarterly dividend of $2.10 per share. Charles River Laboratories International pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or UNH?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Charles River Laboratories International's net income of $25.5M is lower than UnitedHealth Group's net income of $6.3B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while UnitedHealth Group's PE ratio is 12.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.85x versus 0.68x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.85x 913.13x $984.2M $25.5M UNHUnitedHealth Group0.68x 12.70x $109.6B $6.3B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Dollar General Stock Go?
Shares of Dollar General (NYSE:DG) have risen significantly in recent…
How High Can Planet Labs Go Now?
Planet Labs (NYSE:PL) has been a much-talked-about stock for years,…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 34x
Alerts
Sell
19
LULU alert for Jun 9
Lululemon Athletica [LULU] is down 2.36% over the past day.
Sell
46
DOCU alert for Jun 9
Docusign [DOCU] is up 4.37% over the past day.
Sell
15
BRZE alert for Jun 9
Braze [BRZE] is up 3.06% over the past day.
